Evaluation of Efficacy and Safety of AR882 in Gout Patients

Status:
Not yet recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 weeks.

Phase 2

Arthrosi Therapeutics